Skip to content

Comparison of antihypertensive medical care using telemedicine vs. conventional therapy

Comparison of antihypertensive medical care using telemedicine vs. conventional therapy - Telemedicine comparison trial for hypertension

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000025372
Enrollment
450
Registered
2016-12-25
Start date
2017-01-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential Hypertension

Interventions

Telemedicine group: after the initial assessment including a face-to-face interview, the participants will use network-attached sphigmomanometer to measure home blood pressure and consult physician by

Sponsors

Tokyo Women's Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Able to visit Tokyo Women's Medical University Hospital Department of Endocrinology and Hypertension for assessment 2) Wish to try non-face-to-face medical communication and telemedicine 3) Able to perform home blood pressure measurements 4) Age of 20 years or older at time of consent 5) Those with essential hypertension

Exclusion criteria

Exclusion criteria: 1) Those who do not own a smartphone compatible with the telemedicine platform 2) Past history of coronary diseases 3) Those with diabetes mellitus, chronic kidney disease, history of stroke, or peripheral artery disease 4) Those classified as Category III according to the cardiovascular risk chart by Japan Atherosclerosis Society 5) Pregnant women and those with high possibility of becoming pregnant 6) Secondary hypertension, excluding idiopathic hyperaldosteronism and primary aldosteronism after adrenalectomy 7) Those judged by research administrator to be inappropriate for the study

Design outcomes

Primary

MeasureTime frame
Home blood pressure after 1 year

Secondary

MeasureTime frame
1) Major adverse cardiovascular events (coronary events, hospitalization for heart failure, stroke, doubling of serum creatinine) 2) Adverse events 3) Vascular indices: Cardio-Ankle Vascular Index (CAVI), Augmentation Index (AI), Flow Mediated Dilation (FMD), Intima-Media Thickness (IMT), visceral fat area (DUALSCAN) 4) Laboratory data (blood and urine) 5) Questionnaires on quality of life and adherence

Countries

Japan

Contacts

Public ContactJunichi Yatabe

Tokyo Women's Medical University Department of Medicine II, Endocrinology and Hypertension

jyatabe@endm.twmu.ac.jp03-3353-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026